1. Market Research
  2. > Healthcare
  3. > General Medicine and Specialty Medicine Market Trends
  4. > Bone Cancer - Pipeline Review, H2 2013

Bone Cancer - Pipeline Review, H2 2013

  • September 2013
  • -
  • Global Markets Direct
  • -
  • 48 pages

Bone Cancer - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Bone Cancer - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Bone Cancer, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Bone Cancer. Bone Cancer - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Bone Cancer.
- A review of the Bone Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Bone Cancer pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Bone Cancer.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Bone Cancer pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Bone Cancer - Pipeline Review, H2 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Bone Cancer Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Bone Cancer 7
Bone Cancer Therapeutics under Development by Companies 9
Bone Cancer Therapeutics under Investigation by Universities/Institutes 10
Mid Clinical Stage Products 11
Comparative Analysis 11
Early Clinical Stage Products 12
Comparative Analysis 12
Discovery and Pre-Clinical Stage Products 13
Comparative Analysis 13
Bone Cancer Therapeutics - Products under Development by Companies 14
Bone Cancer Therapeutics - Products under Investigation by Universities/Institutes 15
Companies Involved in Bone Cancer Therapeutics Development 16
Debiopharm Group 16
Aileron Therapeutics, Inc. 17
Hawthorn Pharmaceuticals, Inc. 18
Virobay Inc. 19
KaloBios Pharmaceuticals, Inc. 20
Bone Cancer - Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Route of Administration 22
Assessment by Molecule Type 24
Drug Profiles 26
Debio-0719 - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
VBY-825 - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
KB-003 - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
Angiotensin 1-7 - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
ATSP-7041 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
MN-1 - Drug Profile 32
Product Description 32
Mechanism of Action 32
RandD Progress 32
Astrogorgiadiol - Drug Profile 33
Product Description 33
Mechanism of Action 33
RandD Progress 33
Bone Cancer Therapeutics - Drug Profile Updates 34
Bone Cancer Therapeutics - Dormant Products 36
Bone Cancer - Product Development Milestones 37
Featured News and Press Releases 37
Oct 22, 2012: Eleison Enrolls First Patient In Phase II Trial Of Cisplatin For Pediatric Bone Cancer 37
Sep 12, 2012: Indian Supreme Court Asks Novartis To Scale Down Price Of Cancer Drug Glivec 37
Aug 07, 2012: Philips And Celsion Announce FDA Clearance To Commence Phase II Study Of ThermoDox And MR-Guided HIFU In Bone Cancer 37
Mar 02, 2012: Niiki Pharma To Begin Phase I Trial Of NKP-2235 38
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model 39
Jun 22, 2011: Celsion's ThermoDox Featured In Special Issue Of The Open Nanomedicine Journal 39
Jun 06, 2011: Merck And ARIAD Announce Presentation Of Results Of Phase III SUCCEED Trial At ASCO Annual Meeting 41
Jul 11, 2007: Amgen and Daiichi Sankyo Announce Agreement For Denosumab In Japan 42
Mar 14, 2002: Amgen Signs Multi-Year Agreement With International Oncology Network for Aranesp, Neulasta and NEUPOGEN 43
Mar 14, 2002: Amgen Signs Multi-Year Agreement With US Oncology for Aranesp, Neulasta and NEUPOGEN 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 48
Disclaimer 48



List of Tables

Number of Products Under Development for Bone Cancer, H2 2013 7
Products under Development for Bone Cancer - Comparative Analysis, H2 2013 8
Number of Products under Development by Companies, H2 2013 9
Number of Products under Investigation by Universities/Institutes, H2 2013 10
Comparative Analysis by Mid Clinical Stage Development, H2 2013 11
Comparative Analysis by Early Clinical Stage Development, H2 2013 12
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 13
Products under Development by Companies, H2 2013 14
Products under Investigation by Universities/Institutes, H2 2013 15
Debiopharm Group, H2 2013 16
Aileron Therapeutics, Inc., H2 2013 17
Hawthorn Pharmaceuticals, Inc., H2 2013 18
Virobay Inc., H2 2013 19
KaloBios Pharmaceuticals, Inc., H2 2013 20
Assessment by Monotherapy Products, H2 2013 21
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Stage and Molecule Type, H2 2013 25
Bone Cancer Therapeutics - Drug Profile Updates 34
Bone Cancer Therapeutics - Dormant Products 36



List of Figures

Number of Products under Development for Bone Cancer, H2 2013 7
Products under Development for Bone Cancer - Comparative Analysis, H2 2013 8
Products under Development by Companies, H2 2013 9
Products under Investigation by Universities/Institutes, H2 2013 10
Mid Clinical Stage Products, H2 2013 11
Early Clinical Stage Products, H2 2013 12
Discovery and Pre-Clinical Stage Products, H2 2013 13
Assessment by Monotherapy Products, H2 2013 21
Assessment by Route of Administration, H2 2013 22
Assessment by Stage and Route of Administration, H2 2013 23
Assessment by Molecule Type, H2 2013 24
Assessment by Stage and Molecule Type, H2 2013 25



Companies Mentioned

Debiopharm Group
Aileron Therapeutics, Inc.
Hawthorn Pharmaceuticals, Inc.
Virobay Inc.
KaloBios Pharmaceuticals, Inc.

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Liver Transplant Rejection - Pipeline Review, H2 2016

Liver Transplant Rejection - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • September 2016
  • by Global Markets Direct

Liver Transplant Rejection - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Liver Transplant Rejection - Pipeline Review, H2 2016’, provides an overview of the Liver Transplant Rejection ...

Anal Cancer - Pipeline Review, H2 2016

Anal Cancer - Pipeline Review, H2 2016

  • $ 2000
  • Company report
  • August 2016
  • by Global Markets Direct

Anal Cancer - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Anal Cancer - Pipeline Review, H2 2016’, provides an overview of the Anal Cancer pipeline landscape. The report provides comprehensive ...

Omeros Corporation - Product Pipeline Review - 2016

Omeros Corporation - Product Pipeline Review - 2016

  • $ 1500
  • Company report
  • August 2016
  • by Global Markets Direct

Omeros Corporation - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Omeros Corporation - Product Pipeline Review - 2016’, provides an overview of the Omeros Corporation’s pharmaceutical ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.